HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine: What about safety in France?

被引：0
作者：
Ativon, F. [1 ]
Lebeller, C. [2 ]
Schiestel, T. [3 ]
Grandvuillemin, A. [4 ]
Davani, S. [1 ]
Valnet-Rabier, M. B. [1 ]
机构：
[1] Ctr Reg Pharmacovigilance Franche Comte, Besancon, France
[2] Ctr Reg Pharmacovigilance Paris, HEGP, Paris, France
[3] Ctr Reg Pharmacovigilance Paris Fernand Widal, Paris, France
[4] Ctr Reg Pharmacovigilance Bourgogne, Dijon, France
来源：
FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2021年 / 35卷
关键词：
HIV PrEP; TDF/emtricitabine; safety;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PS-117
引用
收藏
页码：147 / 147
页数：1
相关论文
共 50 条
  • [31] Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study
    Baldin, G.
    Ciccullo, A.
    Capetti, A.
    Rusconi, S.
    Sterrantino, G.
    Cossu, M. V.
    Giacomelli, A.
    Lagi, F.
    Latini, A.
    Bagella, P.
    De Luca, A.
    Di Giambenedetto, S.
    Madeddu, G.
    HIV MEDICINE, 2019, 20 (02) : 164 - 168
  • [32] Switching Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide Fumarate (TAF) in Hepatitis B/HIV Co-Infection: A Feasibility Study
    Lok, James
    Veloz, Maria Fernanda Guerra
    Byrne, Ruth
    Carey, Ivana
    Childs, Kate
    Agarwal, Kosh
    Nelson, Mark
    CLINICAL THERAPEUTICS, 2024, 46 (02) : 159 - 163
  • [33] Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial
    Soriano, Vicente
    Arasteh, Keikawus
    Migrone, Horacio
    Lutz, Thomas
    Opravil, Milos
    Andrade-Villanueva, Jaime
    Antunes, Francisco
    Di Perri, Giovanni
    Podzamczer, Daniel
    Taylor, Steve
    Domingo, Pere
    Gellermann, Holger
    de Rossi, Lothar
    ANTIVIRAL THERAPY, 2011, 16 (03) : 339 - 348
  • [34] Effectiveness and safety of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet combination among HIV-infected patients in Turkey: results from a real world setting
    Mete, Bilgul
    Gunduz, Alper
    Karaosmanoglu, Hayat Kumbasar
    Gumuser, Fatma
    Bolukcu, Sibel
    Yildiz, Dilek Sevgi
    Aydin, Ozlem Altuntas
    Bilge, Bilgenur
    Dokmetas, Ilyas
    Tabak, Fehmi
    AFRICAN HEALTH SCIENCES, 2021, 21 (04) : 1593 - 1602
  • [35] Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial
    DeJesus, Edwin
    Rockstroh, Juergen K.
    Henry, Keith
    Molina, Jean-Michel
    Gathe, Joseph
    Ramanathan, Srinivasan
    Wei, Xuelian
    Yale, Kitty
    Szwarcberg, Javier
    White, Kirsten
    Cheng, Andrew K.
    Kearney, Brian P.
    LANCET, 2012, 379 (9835) : 2429 - 2438
  • [36] Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: A European multicenter study
    Si-Ahmed, Si-Nafa
    Pradat, Pierre
    Zoutendijk, Roeland
    Buti, Maria
    Mallet, Vincent
    Cruiziat, Claire
    Deterding, Katja
    Dumortier, Jerome
    Bailly, Francois
    Esteban, Rafael
    Wedemeyer, Heiner
    Janssen, Harry L.
    Zoulim, Fabien
    ANTIVIRAL RESEARCH, 2011, 92 (01) : 90 - 95
  • [37] Impact of antiretroviral therapy containing tenofovir disoproxil fumarate on the survival of patients with HBV and HIV coinfection
    Tsai, Wan-Chen
    Hsu, Wei-Ting
    Liu, Wang-Da
    Sun, Hsin-Yun
    Chuang, Yu-Chung
    Huang, Yu-Shan
    Cheng, Aristine
    Lin, Kuan-Yin
    Huang, Yi-Chia
    Chen, Guan-Jhou
    Huang, Sung-Hsi
    Sheng, Wang-Huei
    Hsieh, Szu-Min
    Hung, Chien-Ching
    Chang, Shan-Chwen
    LIVER INTERNATIONAL, 2019, 39 (08) : 1408 - 1417
  • [38] Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection
    Mesquita, Pedro M. M.
    Rastogi, Rachna
    Segarra, Theodore J.
    Teller, Ryan S.
    Torres, N. Merna
    Huber, Ashley M.
    Kiser, Patrick F.
    Herold, Betsy C.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2012, 67 (07) : 1730 - 1738
  • [39] A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results
    Wohl, David
    Oka, Shinichi
    Clumeck, Nathan
    Clarke, Amanda
    Brinson, Cynthia
    Stephens, Jeffrey
    Tashima, Karen
    Arribas, Jose R.
    Rashbaum, Bruce
    Cheret, Antoine
    Brunetta, Jason
    Mussini, Cristina
    Tebas, Pablo
    Sax, Paul E.
    Cheng, Andrew
    Zhong, Lijie
    Callebaut, Christian
    Das, Moupali
    Fordyce, Marshall
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 72 (01) : 58 - 64
  • [40] Systemic delivery of bictegravir and tenofovir alafenamide using dissolving microneedles for HIV preexposure prophylaxis
    Zhang, Chunyang
    Wu, Yu
    Hutton, Aaron R. J.
    Bin Sabri, Akmal Hidayat
    Hobson, James J.
    Savage, Alison C.
    McCarthy, Helen
    Paredes, Alejandro J.
    Owen, Andrew
    Rannard, Steven P.
    Donnelly, Ryan F.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2024, 660
12345